Millennium Management’s AbbVie ABBV Stock Holding History

Millennium Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$175M	Buy	802,500 +62,300	+8%	+$13.8M	0.07%	244
2025 Q4	$169M	Sell	740,200 -19,800	-3%	-$4.51M	0.07%	244
2025 Q3	$176M	Buy	760,000 +305,300	+67%	+$62.2M	0.08%	222
2025 Q2	$84.4M	Sell	454,700 -663,200	-59%	-$123M	0.04%	497
2025 Q1	$234M	Buy	1,117,900 +612,300	+121%	+$119M	0.12%	118
2024 Q4	$89.8M	Sell	505,600 -27,300	-5%	-$5.02M	0.04%	440
2024 Q3	$105M	Sell	532,900 -482,200	-48%	-$90M	0.05%	389
2024 Q2	$174M	Buy	1,015,100 +67,100	+7%	+$11.1M	0.08%	232
2024 Q1	$173M	Sell	948,000 -252,000	-21%	-$43.4M	0.07%	247
2023 Q4	$186M	Sell	1,200,000 -124,900	-9%	-$18.2M	0.08%	192
2023 Q3	$197M	Buy	1,324,900 +545,500	+70%	+$80.1M	0.1%	145
2023 Q2	$105M	Sell	779,400 -410,100	-34%	-$60.1M	0.05%	348
2023 Q1	$190M	Sell	1,189,500 -363,100	-23%	-$55.5M	0.11%	127
2022 Q4	$251M	Buy	1,552,600 +600,400	+63%	+$92.1M	0.14%	100
2022 Q3	$128M	Sell	952,200 -121,600	-11%	-$17.4M	0.08%	221
2022 Q2	$164M	Sell	1,073,800 -1,023,900	-49%	-$156M	0.1%	127
2022 Q1	$340M	Sell	2,097,700 -914,900	-30%	-$133M	0.18%	53
2021 Q4	$408M	Buy	3,012,600 +1,534,800	+104%	+$181M	0.21%	57
2021 Q3	$159M	Sell	1,477,800 -260,000	-15%	-$29.7M	0.1%	161
2021 Q2	$196M	Buy	1,737,800 +45,700	+3%	+$5.15M	0.12%	105
2021 Q1	$183M	Buy	1,692,100 +790,500	+88%	+$84.6M	0.13%	98
2020 Q4	$96.6M	Buy	901,600 +550,400	+157%	+$52.9M	0.07%	222
2020 Q3	$30.8K	Sell	351,200 -4,000	-1%	-$377K	0.04%	547
2020 Q2	$34.9M	Sell	355,200 -673,900	-65%	-$59.3M	0.05%	454
2020 Q1	$78.4M	Buy	1,029,100 +363,000	+54%	+$30.9M	0.18%	92
2019 Q4	$59M	Buy	666,100 +498,300	+297%	+$41.4M	0.07%	300
2019 Q3	$12.7M	Buy	+167,800	New	+$11.5M	0.02%	1108
2014 Q4	–	Sell	-5,000	Closed	-$178K	–	3865
2014 Q3	$178K	Sell	5,000 -600	-11%	-$33.3K	﹤0.01%	3463
2014 Q2	$316K	Buy	+5,600	New	+$294K	﹤0.01%	2842

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management's ABBV Position: Q1 2026 in Review

Millennium Management increased its AbbVie (ABBV) stake by 3,297% in Q1 2026, buying an estimated $145M and bringing the position to 675,757 shares worth $147M. The position accounts for 0.06% of the portfolio, ranked #303.

Millennium Management first reported a position in ABBV in Q2 2013 and has held it in 49 quarters since. The position peaked at $467M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Millennium Management held 675,757 shares of AbbVie worth $147M as of Q1 2026.
Millennium Management bought 655,864 AbbVie shares in Q1 2026, an estimated $145M.
AbbVie made up 0.06% of Millennium Management's portfolio in Q1 2026, its #303 holding.
Millennium Management first reported a position in AbbVie in Q2 2013 and has held it in 49 quarters since.
Millennium Management's AbbVie position peaked at $467M in Q3 2025.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.